Eli Lilly Partners with OpenAI to Combat Drug-Resistant Bacteria

👉 Key Highlights:

📍 Eli Lilly partners with OpenAI to leverage generative AI for new antimicrobials.

📍 Focus on treating drug-resistant pathogens through innovative AI technology.

📍 AMR is a major global health threat, exacerbated by misuse and overuse of antimicrobials.

📍 Partnership underscores Lilly's commitment to addressing significant health challenges.

📍 Collaboration aims to accelerate the discovery of novel antimicrobials.

📍 Lilly’s Social Impact Venture Capital Portfolio committed $100 million to AMR Action Fund.

📍 AMR Action Fund targets providing 2-4 new antibiotics by 2030.

📍 Latest investments in biotech companies targeting various infections announced in April 2023.

👉 Context/Background:

Antimicrobial resistance (AMR) is a critical public health threat globally, driven by the misuse and overuse of antimicrobials. This partnership between Eli Lilly and OpenAI aims to harness AI to discover new treatments for drug-resistant bacteria.

👉 Expert Statement:

🗨️ "Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance." - Diogo Rau, EVP, Eli Lilly.

🗨️ "Advanced AI has the potential to deliver innovative breakthroughs in pharma, and we're committed to working together with industry leaders to deliver tangible benefits for patients." - Brad Lightcap, COO, OpenAI.